• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MDM2对软组织肿瘤潜在分子致病疗法的影响

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors.

作者信息

Sun Sylvia Yao, Crago Aimee

机构信息

Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, 417 E 618 St, New York, NY 10065, USA.

Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

出版信息

J Clin Med. 2023 May 24;12(11):3638. doi: 10.3390/jcm12113638.

DOI:10.3390/jcm12113638
PMID:37297833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10253559/
Abstract

Murine double minute 2 (MDM2, gene name ) is an oncogene that mainly codes for a protein that acts as an E3 ubiquitin ligase, which targets the tumor suppressor protein p53 for degradation. Overexpression of MDM2 regulates the p53 protein levels by binding to it and promoting its degradation by the 26S proteasome. This leads to the inhibition of p53's ability to regulate cell cycle progression and apoptosis, allowing for uncontrolled cell growth, and can contribute to the development of soft-tissue tumors. The application of cellular stress leads to changes in the binding of MDM2 to p53, which prevents MDM2 from degrading p53. This results in an increase in p53 levels, which triggers either cell cycle arrest or apoptosis. Inhibiting the function of MDM2 has been identified as a potential therapeutic strategy for treating these types of tumors. By blocking the activity of MDM2, p53 function can be restored, potentially leading to tumor cell death and inhibiting the growth of tumors. However, further research is needed to fully understand the implications of MDM2 inhibition for the treatment of soft-tissue tumors and to determine the safety and efficacy of these therapies in clinical trials. An overview of key milestones and potential uses of MDM2 research is presented in this review.

摘要

小鼠双微体2(MDM2,基因名称)是一种癌基因,主要编码一种作为E3泛素连接酶的蛋白质,该酶靶向肿瘤抑制蛋白p53进行降解。MDM2的过表达通过与p53结合并促进其被26S蛋白酶体降解来调节p53蛋白水平。这导致p53调节细胞周期进程和凋亡的能力受到抑制,从而允许细胞不受控制地生长,并可能导致软组织肿瘤的发生。细胞应激的应用会导致MDM2与p53结合的变化,从而阻止MDM2降解p53。这导致p53水平升高,进而触发细胞周期停滞或凋亡。抑制MDM2的功能已被确定为治疗这类肿瘤的一种潜在治疗策略。通过阻断MDM2的活性,可以恢复p53的功能,这可能导致肿瘤细胞死亡并抑制肿瘤生长。然而,需要进一步研究以充分了解抑制MDM2对软组织肿瘤治疗的影响,并确定这些疗法在临床试验中的安全性和有效性。本综述介绍了MDM2研究的关键里程碑和潜在用途概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/90a908b04e9e/jcm-12-03638-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/d13085ead101/jcm-12-03638-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/f2f6b93998ef/jcm-12-03638-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/90a908b04e9e/jcm-12-03638-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/d13085ead101/jcm-12-03638-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/f2f6b93998ef/jcm-12-03638-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e3/10253559/90a908b04e9e/jcm-12-03638-g003.jpg

相似文献

1
MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors.MDM2对软组织肿瘤潜在分子致病疗法的影响
J Clin Med. 2023 May 24;12(11):3638. doi: 10.3390/jcm12113638.
2
The mdm2 proto-oncogene.小鼠双微体2原癌基因
Leuk Lymphoma. 1997 Jul;26(3-4):227-38. doi: 10.3109/10428199709051772.
3
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.人肿瘤细胞中 Mdm2 E3 连接酶抑制的功能分析及其后果。
Oncogene. 2012 Nov 8;31(45):4789-97. doi: 10.1038/onc.2011.625. Epub 2012 Jan 23.
4
Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.逃逸还是消失:通过MDM2介导的泛素化作用控制p53的命运
Anticancer Agents Med Chem. 2015;16(2):174-89. doi: 10.2174/1871520615666150907093358.
5
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.药物抑制 Mdm2 会引发小鼠结肠肿瘤和人结肠癌细胞的生长停滞,并促进 DNA 断裂。
Mol Carcinog. 2012 May;51(5):363-78. doi: 10.1002/mc.20795. Epub 2011 May 6.
6
A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.反馈回路中的一个新转折:p53激活需要应激激活的MDM2去稳定化。
Cell Cycle. 2005 Mar;4(3):411-7. doi: 10.4161/cc.4.3.1522. Epub 2005 Mar 2.
7
Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.通过抑制 Mdm2 E3 连接酶来重新激活 p53:一种新的抗肿瘤方法。
Curr Cancer Drug Targets. 2011 Oct;11(8):987-94. doi: 10.2174/156800911797264789.
8
MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.MDM2 E3 连接酶活性对于 p53 调节和细胞周期完整性至关重要。
PLoS Genet. 2022 May 19;18(5):e1010171. doi: 10.1371/journal.pgen.1010171. eCollection 2022 May.
9
Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.作为抗癌药物的MDM2癌蛋白小分子拮抗剂。
Curr Cancer Drug Targets. 2005 Feb;5(1):57-68. doi: 10.2174/1568009053332672.
10
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.MDM2、MDMX 和 p73 在野生型 p53 缺失的情况下调节细胞周期进程。
Proc Natl Acad Sci U S A. 2021 Nov 2;118(44). doi: 10.1073/pnas.2102420118.

引用本文的文献

1
Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer risk? A meta-analysis.TP53基因的Arg72Pro多态性和MDM2基因的T309G多态性与膀胱癌风险相关吗?一项荟萃分析。
Afr Health Sci. 2024 Sep;24(3):118-127. doi: 10.4314/ahs.v24i3.16.
2
Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?软组织肉瘤的全身治疗:我们正在取得成效吗?
Cancers (Basel). 2025 Mar 5;17(5):889. doi: 10.3390/cancers17050889.
3
Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.胆管癌靶向治疗:作用机制与耐药性

本文引用的文献

1
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.BI 907828(MDM2-p53 拮抗剂)对比多柔比星治疗晚期去分化脂肪肉瘤的Ⅱ/Ⅲ期 Brightline-1 试验。
Future Oncol. 2023 Mar;19(9):621-629. doi: 10.2217/fon-2022-1291. Epub 2023 Mar 29.
2
Targeting p53 pathways: mechanisms, structures, and advances in therapy.靶向 p53 通路:机制、结构和治疗进展。
Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1.
3
Detection of gene amplification on tissue microarray-based Fluorescence In-Situ Hybridization (FISH) in well-differentiated and dedifferentiated liposarcomas, displaying a wide morphological spectrum: A validation study at a tertiary cancer referral centre.
Am J Pathol. 2025 Mar;195(3):437-452. doi: 10.1016/j.ajpath.2024.11.005. Epub 2024 Dec 19.
4
MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53.MDM2 通过靶向 p53 对于维持上皮细胞的内稳态是必不可少的。
J Innate Immun. 2024;16(1):397-412. doi: 10.1159/000539824. Epub 2024 Aug 12.
基于组织微阵列的荧光原位杂交(FISH)检测在分化良好和去分化脂肪肉瘤中的基因扩增,表现出广泛的形态谱:在三级癌症转诊中心的验证研究。
Indian J Pathol Microbiol. 2022 Jan-Mar;65(1):65-75. doi: 10.4103/IJPM.IJPM_1238_20.
4
Mdm2 and MdmX: Partners in p53 Destruction.Mdm2 和 MdmX:p53 破坏的伙伴。
Cancer Res. 2021 Apr 1;81(7):1633-1634. doi: 10.1158/0008-5472.CAN-21-0145.
5
MDM2 Amplified Sarcomas: A Literature Review.MDM2基因扩增的肉瘤:文献综述
Diagnostics (Basel). 2021 Mar 11;11(3):496. doi: 10.3390/diagnostics11030496.
6
The 2020 WHO Classification of Tumors of Bone: An Updated Review.2020 年世卫组织骨肿瘤分类:更新综述。
Adv Anat Pathol. 2021 May 1;28(3):119-138. doi: 10.1097/PAP.0000000000000293.
7
p53: 800 million years of evolution and 40 years of discovery.p53:8 亿年的进化与 40 年的发现。
Nat Rev Cancer. 2020 Aug;20(8):471-480. doi: 10.1038/s41568-020-0262-1. Epub 2020 May 13.
8
The role of amplification and overexpression in therapeutic resistance of malignant tumors.扩增和过表达在恶性肿瘤治疗耐药中的作用。
Cancer Cell Int. 2019 Aug 22;19:216. doi: 10.1186/s12935-019-0937-4. eCollection 2019.
9
Multi-omics profiling of calcium-induced human keratinocytes differentiation reveals modulation of unfolded protein response signaling pathways.钙诱导的人角质形成细胞分化的多组学分析揭示了未折叠蛋白反应信号通路的调节。
Cell Cycle. 2019 Sep;18(17):2124-2140. doi: 10.1080/15384101.2019.1642066. Epub 2019 Jul 22.
10
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.MDM2-TP53抑制剂BI-907828在携带MDM2扩增的去分化脂肪肉瘤患者来源异种移植模型中的抗肿瘤活性。
Clin Transl Oncol. 2020 Apr;22(4):546-554. doi: 10.1007/s12094-019-02158-z. Epub 2019 Jun 14.